Alec Broers becomes chairman of Bio Nano Consulting

Brings extensive industry, academic and scientific expertise to company

Bio Nano Consulting, a UK specialist in bio and nanotechnology partnerships between the academic and industrial sectors, has appointed Professor Lord Alec Broers as chairman of the board.

Broers has extensive industry, academic and scientific expertise and was chairman of the House of Lords Science and Technology Select Committee between 2004 and 2007.

At Bio Nano Consulting he will facilitate ongoing partnerships between academia and the wider life science and technology industries.

Educated at Melbourne University and the University of Cambridge, Broers subsequently worked in r&d at IBM laboratories in the US for 19 years, ultimately taking responsibility for the company’s chip development.

Broers returned to the UK in 1984 as head of Electrical Engineering at Cambridge University and Fellow of Trinity College. He subsequently became head of the Department of Engineering and Master of Churchill College.

More recently, Broers was Vice Chancellor of Cambridge University and president of the Royal Academy of Engineering from 2001 to 2006. He was knighted in 1998 for services to education before being made a life peer in 2004.

Bio Nano Consulting is a joint venture of Imperial College London and University College London that specialises in solutions to industry across the life sciences and technology sectors.

You may also like

Research & Development

NanoKTN facilitates cancer drug partnership

BNC and London University School of Pharmacy sign service level agreement
Manufacturing

Bio Nano Consulting clinches cancer drug formulation contract

Signs agreement with University of London School of Pharmacy
Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Subscribe now